SCHEMBL29568154

SCHEMBL29568154

O=[N+]([O-])c1ccccc1S(=O)(=O)Nc1nc(Oc2ccccc2)cc(-c2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 1/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ KDM1A O60341 1/20 0.47
▸ MAOA P21397 1/20 0.47
▸ TDP1 Q9NUW8 2/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ MMP1 P03956 1/20 0.46
▸ MMP2 P08253 1/20 0.46
▸ MMP9 P14780 1/20 0.46
▸ MMP8 P22894 1/20 0.46
▸ MMP13 P45452 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ NFKBIA P25963 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26812715 1.00 AR (0.47) ARMEN1KMT2AKDM1AMAOA
SCHEMBL26812660 0.83 MAPT (0.58) MEN1KMT2ATDP1CA2MMP1
SCHEMBL24309652 0.82 TDP1 (0.50) MEN1KMT2ATDP1MAPK1MAPT
SCHEMBL29567152 0.82 TDP1 (0.50) MEN1KMT2ATDP1MAPK1MAPT
SCHEMBL24310225 0.82 MAPT (0.52) MEN1KMT2ATDP1MAPK1MAPT
SCHEMBL26812645 0.81 PGR (0.61) ARMEN1KMT2AKDM1ATDP1
SCHEMBL26812683 0.80 MAPT (0.48) MEN1KMT2ATDP1MMP1MMP2
SCHEMBL26812913 0.80 ACLY (0.48) MEN1KMT2ATDP1MAPK1MAPT
SCHEMBL26806813 0.80 MAPT (0.61) MEN1KMT2ATDP1MAPK1MAPT
SCHEMBL24310218 0.78 TDP1 (0.46) MEN1KMT2ATDP1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback